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Abstract: Cystic fibrosis (CF) is a genetic disease caused by abnormal chloride transport 
across cellular membranes. In the respiratory tract, this molecular defect causes obstruction of 
the airways by mucus and chronic endobronchial infection. The majority of patients suffer early 
death from chronic respiratory disease. Pseudomonas aeruginosa is the predominant chronic 
airway pathogen in older children and adults with CF and is associated with worse outcomes. 
However, overall survival in CF has been greatly improved in recent decades due in large part 
to the aggressive treatment of chronic infections such as P . aeruginosa. While intravenous and 
oral antibiotics are commonly used in the management of CF respiratory infections, inhaled 
anti-infective therapies offer the benefit of delivering the drug directly to the site of infection 
and avoiding potential toxicities associated with systemic absorption. Aztreonam lysine (AZLI) 
has recently been developed as an inhaled antibiotic for chronic use in CF patients with endo-
bronchial P . aeruginosa infection. This paper reviews background data and the clinical studies 
which contributed to AZLI’s formal FDA approval and growing role in the management of CF 
pulmonary disease.
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Introduction
Cystic fibrosis (CF) is the most common fatal genetic disorder affecting Caucasian 
populations. While CF is a multisystem disease involving the pancreas, liver, and 
gastrointestinal tract among other organs, most patient morbidity and mortality is 
related to advanced lung disease. Pulmonary manifestations of CF are characterized 
by chronic, recurring airway infection, inflammation, bronchiectasis, and progres-
sively worsening obstructive lung physiology. Chronic respiratory failure is the most 
common cause of death.1
The overall life expectancy for patients suffering from CF has improved signifi-
cantly over the last several decades, with mean survival now exceeding 35 years.2 
Key factors in the management of CF which have led to improved outcomes include 
aggressive treatment of respiratory infections, daily chest physiotherapy combined 
with aerosolized medications (such as dornase alpha and hypertonic saline) aimed to 
improve clearance of mucus, and maximal treatment of comorbid conditions such as 
nutritional deficiency and CF-related diabetes mellitus.1,3
Pseudomonas aeruginosa is a common airway pathogen in CF and is associ-
ated with a decline in lung function and an overall increase in mortality.4,5 The 
majority of older adolescents and adults with CF are chronically infected with 
P .   aeruginosa.2 Although aggressive use of antibiotic regimens at the earliest sign Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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of P . aeruginosa infection may delay chronic airway 
  colonization, P .   aeruginosa is difficult or impossible to 
eradicate in most patients once colonization has occurred 
due to several factors such as reduced mucociliary clear-
ance, altered innate immune defense mechanisms, com-
partmentalization of infection, biofilm production, and 
heterogeneous antibiotic resistance.3 Therefore the manage-
ment of P . aeruginosa in CF lung disease is focused both on 
aggressive treatment during periods of acute illness and on 
chronic anti-infective maintenance strategies to help control 
endobronchial infection.6 Antibiotic agents with utility 
against P . aeruginosa can be administered via intravenous 
(IV), oral, and inhaled formulations. Each method has 
unique advantages (systemic therapeutic targeting for IV , 
convenience of oral and directed topical effect for inhaled 
therapies) and disadvantages (line access, treatment burden, 
and systemic toxicity for IV; minimal available agents and 
gastrointestinal intolerance for oral; and localized intoler-
ance, potential long-term toxicity, and treatment burden 
for inhaled therapies).
Recently published guidelines recommend the regular use 
of inhaled tobramycin in patients with chronic P .   aeruginosa 
infection, citing its proven benefits in improving lung 
  function and decreasing exacerbations.7 Data from the US 
CF Foundation Patient Registry suggests that almost 70% 
of eligible patients use inhaled tobramycin.2 However, the 
regular use of inhaled tobramycin may be limited in some 
patients by side effects, long-term toxicity, expense, and the 
treatment burden associated with time of administration. 
Additionally, there is ongoing concern for the emergence 
of antibiotic resistance and increasing MICs (minimum 
inhibitory concentrations) for P . aeruginosa isolates with 
chronic tobramycin exposure, of which the long-term clini-
cal implications have not yet been elucidated.3 Therefore the 
development of alternative inhaled antibiotic therapies (such 
as aztreonam lysine, colistin/colistimethate, liposomal ami-
kacin, ciprofloxacin, levofloxacin, and fosfomycin) for use 
in CF has been an area of significant focus.
Aztreonam is a monobactam antibiotic with excellent 
coverage of aerobic Gram-negative bacterial species includ-
ing P . aeruginosa. It has been available in IV formulation 
for decades, but aztreonam lysine (AZLI) was recently 
developed in an inhaled formulation to be delivered with a 
novel and potentially more patient-friendly nebulizer device. 
While aztreonam is traditionally considered to have strictly 
Gram-negative coverage, an early study of AZLI suggests that 
limited activity may exist for some strains of   Staphylococcus 
aureus.8 The purpose of this paper is to review AZLI’s 
  development and the existing clinical data supporting its use 
for the management of chronic airway infection in CF.
Pathogenesis of CF
Over the past several decades much has been learned about 
the molecular basis of CF.9 It is an autosomal recessive dis-
ease whereby mutations in the gene encoding the cystic fibro-
sis transmembrane conductance regulator protein (CFTR) 
on chromosome 7 lead to defective or insufficient CFTR.10 
Research into mutations, modifying genes, and severity of 
disease is currently ongoing.1 The ∆F508 mutation is the most 
prevalent CFTR mutation among the CF population; however, 
multiple gene mutations have been and are currently being 
identified, with 1876 listed in the CFTR Mutation Database 
as of April 2011.2,10,11 The CFTR protein is a chloride channel 
responsible for chloride transport across cell membranes. In 
the respiratory tract, abnormal ion flow across the respiratory 
epithelium results in an intracellular accumulation of chloride 
ions and ultimately depletion of chloride, sodium and water 
from the airway lumen. The airway surface liquid layer is 
decreased which leads to poor mucociliary clearance and 
the development of thick, viscous mucus.1,9 The molecular 
pathway of CF results in an airway environment where bacte-
ria can survive and thrive. Over time, chronic endobronchial 
infection and inflammation result in disruption of the airway 
epithelium and bronchiectasis. The physiologic consequence 
is progressive obstructive lung physiology, respiratory insuf-
ficiency, and death from chronic respiratory failure in the vast 
majority of patients (Figure 1).
Airway destruction  Airway inflammation
Chronic respiratory failure
Abnormal CFTR
Airway dehydration
Abnormal mucociliary clearance
Obstructive lung disease
Bacterial colonization Chronic infection
Figure 1 Mechanism of CF pulmonary disease.
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CF microbiology  
and the importance of P. aeruginosa
Patients with CF acquire chronic airway microbial pathogens 
in a predictable manner (Figure 2). Early in childhood, the 
most common pathogens include S. aureus and Haemophilus 
influenzae. As patients transition through adolescence to 
adulthood, P . aeruginosa becomes the most prevalent endo-
bronchial infection, with approximately 80% of adults having 
consistent positive cultures from the respiratory tract.2
The acquisition of P . aeruginosa is an important 
event in the natural history of CF lung disease, as chronic 
P .   aeruginosa infection is associated with both a decrease 
in lung function and lower overall survival.4 This profound 
clinical consequence is associated with a transition from a 
nonmucoidal to mucoidal phenotype, and the subsequent 
development of biofilms and a resultant increase in bacterial 
virulence and multidrug resistance.12
Inhaled antibiotics in CF
Administration of antibiotic agents directly into the airways of 
patients with CF offers several potential benefits. The desired 
drug can reach the target area of infection without involving the 
systemic circulation. This may avoid issues with nephrotoxic-
ity, ototoxicity, and other problems   commonly   associated with 
various IV antipseudomonal agents such as   aminoglycosides 
(gentamicin, tobramycin, and amikacin) and colistin. 
  Furthermore, the concentration of drug in the airway itself may 
reach levels which exceed the MIC, thereby offering clinical 
efficacy even though a particular agent may be “resistant” on 
standard drug susceptibility testing.
Common side effects associated with inhaled antibiotic 
agents include manifestations of bronchospasm such as 
wheezing, chest tightness or cough, throat discomfort, and 
hoarseness. Side effects can be related to patient-specific 
sensitivity (idiosyncratic or sensitization with chronic use), 
drug formulation (pH, chemical properties, excipients, 
esthetic quality), and drug delivery methods (particulate 
size nebulization devices). Achievement of optimal particle 
sizes (1–5 µm) for delivery to the small conducting air-
ways is dependent on airway anatomy, minute ventilation, 
nebulization device, and nebulized flow rate.13,14 Traditional 
methods for delivery of aerosolized agents, which include 
jet and ultrasonic nebulizers, may take 20–30 minutes for 
one treatment and, therefore, result in a substantial treatment 
burden for individual patients.
Inhaled tobramycin was the first inhaled antibiotic 
  specifically approved for the treatment of P . aeruginosa 
infection in CF. It is clinically available in a pre-mixed 
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Figure 2 Prevalence of endobronchial infection.
Reproduced with permission by Cystic Fibrosis Foundation Patient Registry, 2009 Annual Data Report, Bethesda, MD.2 © 2011 Cystic Fibrosis Foundation.
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300 mg/5 mL vial (TOBI®, Novartis Pharmaceuticals, 
Basel, Switzerland) for twice daily use. Inhaled tobramy-
cin has widespread use, a favorable side effect profile, and 
proven efficacy including improvement in lung function and 
decreased need for hospitalizations.15 Standard guidelines 
recommend its use on an alternating on–off 4-week cycle 
for patients with chronic P . aeruginosa infection to reduce 
exacerbations and improve lung function.7 Additionally, 
alternating cycles have been favored historically as an effort 
to minimize development of tobramycin resistance, namely 
bacterial impermeability, with chronic therapy.16 Many cen-
ters will also use it in   combination with oral or IV antibiotics 
in the treatment of acute pulmonary exacerbations, however 
there is no clear medical literature to support this practice.14,17 
Side effects which can be associated with inhaled tobramycin 
include hoarseness and tinnitus. Long-term use may also have 
  cumulative effects on ototoxicity and nephrotoxicity.
Colistin has also been commonly used to treat chronic 
endobronchial P . aeruginosa infection, particularly in 
Europe.18 One trial comparing inhaled colistin to inhaled 
tobramycin found a greater improvement in lung function 
with tobramycin, but both drugs were well-tolerated.19 
Colistin must be dispensed in powder form and mixed into 
aqueous solution at the time of administration, as toxicity 
from pre-mixed solution has been reported.20   Aerosolization 
of standard IV amikacin has also been utilized in CF21, 
and may be particularly useful in the chronic treatment of 
  Mycobacterium abscessus.22
Aztreonam
Aztreonam is a monobactam antibiotic developed in the 
early 1980s. It has excellent activity against a wide range 
of   Gram-negative organisms, including P . aeruginosa.23,24 
Aztreonam binds to penicillin-binding proteins and causes 
inhibition of bacterial cell wall synthesis and ultimately 
death of the bacterial cell. The respiratory tract receives 
good penetrance,25 and several studies have demonstrated 
both in vitro and clinical evidence of benefits of intravenous 
aztreonam in patients with CF.26–28 Aztreonam’s utility against 
P . aeruginosa and potentially other Gram-negative organisms 
that may be associated with CF endobronchial infections (such 
as Burkholderia cepacia complex [BCC]) make it an attractive 
antibiotic to be developed in inhaled formulations.
Potential side effects of IV aztreonam include rash, 
  nausea, vomiting, diarrhea, and elevation of liver enzymes. 
The IV aztreonam formulation contains the arginine salt 
which has the clinical potential to worsen airway inflamma-
tion or cause bronchoconstriction. Arginine is a substrate 
for nitric oxide production which has been associated with 
airway inflammation in asthma.29,30 However, data are con-
flicting in CF. Nitric oxide formation has been shown to be 
reduced in CF airways which may lead to airway obstruction, 
and inhaled L-arginine has been investigated as a therapeutic 
approach in CF to improve exhaled nitric oxide and lung 
function.31 Due to uncertainty in nitric oxide balance in indi-
vidual CF patients needing to avoid excessive nitric oxide 
formation, the lysine salt was chosen as a potentially safer 
formulation of aztreonam for aerosolized use.8
Delivery device for inhaled 
aztreomam
AZLI (Cayston®; Gilead Sciences, Foster City, CA) has been 
specifically developed for use with the Altera® Nebulizer 
System which uses eFlow® electronic nebulizer technology 
(both from Pari Innovative Manufacturers Inc, Midlothian, 
VA). There are several potential benefits of drug delivery 
via this electronic, multi-use nebulizer device. The eFlow® 
utilizes a vibrating, perforated membrane to generate a high-
speed aerosol. With this novel aerosolization format, AZLI 
particle generation is reported as 3.6 ± 0.1 µm26 which is in 
the optimal range of particulate size for delivery to the small 
conducting airways (1–5 µm).11,13 Highly efficient delivery is 
achieved as a 1 mL dosage volume delivered over approxi-
mately 2–3 minutes, a delivery rate two to four times that of 
traditional high-quality jet nebulizers.8 These features may 
improve patient satisfaction and overall compliance.
Clinical studies of inhaled 
aztreonam
AZLI was developed and systematically evaluated by a col-
laborative, international effort over the past decade. These 
studies are summarized in Table 1. Initial pre-clinical data 
and Phase 1 study results were reported by Gibson and 
colleagues in 2006.8 A total of 18 adult and 17 adolescent 
patients with a forced expiratory volume over 1 second 
(FEV1) $ 40% predicted were randomized to receive AZLI 
vs placebo in daily escalating doses to determine the bioactiv-
ity of the drug in sputum; systemic and sputum pharmacoki-
netics; in vitro microbiological activity; and clinical safety. 
AZLI was well-tolerated at doses of 75 mg, 150 mg, and 
225 mg. Sputum drug concentrations exceeded the MIC50 
against multidrug resistant P . aeruginosa as well as BCC for 
4 hours after drug administration. Systemic absorption was 
minimal in adult patients receiving the 75 mg dose (Cmax 
0.419 ± 0.155 µg/mL). This work provided the background 
for further clinical development of AZLI.Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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Table 1 Summary of AZLi clinical trials
Author Patient  
population
Study  
design
Primary  
endpoint
Main  
results
1. Gibson et al8 -35 adult and 
adolescents
-FEv1 $ 40%
Phase I, double-blind,  
placebo-controlled,  
dose-escalation trial
Pharmacokinetics  
and tolerability
AZLi was well tolerated  
and sputum concentrations  
exceeded MiC of Pa
2.   Retsch-Bogart  
et al32
-105 patients,  
age $ 13 years  
-FEv1 $ 40%
Phase ii, randomized,  
double-blind,  
placebo-controlled trial  
of AZLi vs placebo for 14 days
Percent change  
in FEv1 at end  
of 14 days
– No significant change in FEV1 
–   Trend of greater improvement in lung 
function in those with worse baseline FEv1
– 75 mg dose determined to be ideal
3. McCoy  et al34 -246 patients,  
age $ 6 years
-FEv1 25%–75%
Phase ii, randomized,  
double-blind,  
placebo- controlled trial  
of AZLi vs placebo for 28 days
Time to need for  
additional anti-Pa  
antibiotics
–   Increased time to need for additional anti-
Pa antibiotics
–   improved FEv1, patient symptoms score, 
sputum Pa density
4.   Retsch-Bogart  
et al35
-164 patients,  
age $ 6 years
-FEv1 25%–75%
Phase ii, randomized,  
double-blind,  
placebo-controlled trial  
of AZLi vs placebo for 28 days
Change in  
patient-reported  
respiratory  
symptom score
–   Significant improvement in self-reported 
symptom scores
– improved FEv1 and sputum Pa density
5. Oermann  et al36 -274 patients,  
age . 8 years  
(mean age 28.5)
-previous participant  
in study 3 or 4
Phase iii, 18 month open label  
trial evaluating long-term use  
of alternating months of AZLi
Safety  
and efficacy
– Long-term use was well tolerated
–   At the end of each treatment cycle,  
improved FEv1, symptom scores,  
sputum Pa density
– improved weight over treatment course
6.   wainwright  
et al37
-157 patients,  
age $ 6 years
-FEv1 . 75%
Randomized, double-blind,  
placebo-controlled trial  
of AZLi vs placebo for 28 days
Change in  
patient-reported  
respiratory  
symptom score
– No significant change in symptom score
– improved FEv1 and sputum Pa density
Abbreviations: Pa, Pseudomonas aeruginosa; FEv1, forced expiratory volume in 1 second; AZLi, aztreonam lysine.
A Phase II investigation of AZLI was reported by 
  Retsch-Bogart and colleagues.32 In this double-blind, ran-
domized, placebo-controlled multicenter trial involving 20 
US CF centers, patients with mild and moderate lung disease 
were recruited to evaluate the safety, tolerability and effi-
cacy of AZLI over a 14-day treatment period. A total of 105 
adult and adolescent patients with FEV1 $ 40% predicted 
were randomized to receive AZLI twice daily at doses of 
75 mg or 225 mg vs placebo. The primary outcome of the 
study was percent change in FEV1 at day 14 in the patients 
receiving 225 mg of AZLI twice daily. There was no signifi-
cant change in this variable. However, secondary analysis 
determined that there was a trend of greater improvement 
in lung function in those individuals with lower baseline 
lung function. AZLI was well tolerated in general, with 
slightly more adverse events (primarily cough) associated 
with higher treatment dose. Peak serum concentrations of 
AZLI were substantially lower, with a median peak of 0.69 
(0.02–1.74) µg/mL in the 75 mg group and median peak of 
1.49 (0.01–3.84) µg/mL in the 225 mg group,27 than those 
of a single 500 mg intravenous administration (54 µg/mL).33 
Median sputum   concentrations (279 [22.6–1290] µg/g in 
the 75 mg group and 900 [80.2–5689] µg/g in the 225 mg 
group) were significantly above the MIC50 for P . aeruginosa 
isolates (#1 µg/mL and 4 µg/mL in the 75 mg and 225 mg 
groups, respectively), and treatment with the study drug was 
not associated with new endobronchial pathogens. This study 
is significant in that it led investigators to focus on 75 mg 
dosing for further clinical trials.
McCoy and colleagues described the results of another 
Phase II, multicenter trial evaluating the utility of AZLI in 
patients with moderate-to-severe CF lung disease already 
on treatment with cyclical months of inhaled tobramycin.34 
Patients with chronic P . aeruginosa infection aged 6 years and 
older with baseline FEV1 values between 25% and 75% of 
predicted values were enrolled from 56 US CF centers. Other 
significant inclusion criteria included at least three monthly 
courses of inhaled tobramycin in the year before the study 
and room air oxygen saturations $90% on room air. Patients 
with BCC or on chronic oral corticosteroids were excluded. 
Randomization occurred in a 1:1:1 fashion to three study 
groups: AZLI 75 mg twice daily; AZLI 75 mg three times 
daily; or placebo. The primary study endpoint was time to 
need additional antipseudomonal antibiotics for treatment of 
symptoms of a pulmonary exacerbation. Secondary endpoints 
included change in clinical symptoms, pulmonary function 
testing, time to hospitalizations, total number of hospitaliza-
tions, weight, and P . aeruginosa density in sputum.Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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A total of 246 individuals were enrolled in the study. 
After randomization, all patients received an open-labeled 
28-day run-in treatment course with inhaled tobramycin. The 
patients were generally adults (mean age 26.2 years) with 
moderately to severely impaired lung function (mean FEV1 
55.1% predicted), who had averaged over five courses of 
inhaled tobramycin in the year before the study. Drop-out rate 
in the study was high, with 35 patients discontinuing the study 
during the tobramycin run-in period (mostly due to adverse 
events), leaving 211 patients for intention-to-treat analysis. 
Of this group, 173 completed the AZLI/placebo treatment 
period, but only 90 patients fully completed the trial. The 
primary reasons for discontinuation of study therapy were 
adverse events (mostly related to cough and other expected 
CF-related symptoms) which were not statistically significant 
between groups.28
The efficacy of AZLI was demonstrated by a 21-day 
increase in the median time to need additional antipseudomonal 
antibiotics in the pooled AZLI treatment groups vs those 
receiving placebo. Patient-reported symptom scores, mean 
FEV1 after treatment, and P . aeruginosa density were all 
significantly improved in the AZLI treatment groups. AZLI 
was generally well tolerated with no difference in adverse 
events between placebo and treatment groups.28
Retsch-Bogart and colleagues then reported a Phase II, 
randomized, double-blind, placebo-controlled study involv-
ing 53 CF centers in Australia, New Zealand, Canada, 
and the US.35 Whereas McCoy’s study evaluated AZLI in 
patients generally adherent to chronic CF therapies aimed at 
P .   aeruginosa, this study specifically evaluated its effective-
ness in patients receiving less maintenance therapies than 
standard guidelines recommend.
A total of 164 patients aged 6 years and older with chronic 
P . aeruginosa infection and FEV1 between 25% and 75% of 
predicted were randomized in a 1:1 manner to receive AZLI 
75 mg TID or placebo for 28 days. Monitoring occurred for 
14 days following the treatment period. The primary endpoint 
was change in patient-reported respiratory symptoms as 
evaluated by the CF Questionnaire-Revised (CFQ-R) respi-
ratory scale. Change in lung function, sputum P . aeruginosa 
density, and key nonrespiratory CFQ-R scores were second-
ary endpoints.29
Following 28 days of treatment, when compared to pla-
cebo, patients receiving AZLI had a significant improvement 
in mean CFQ-R scores. Furthermore, lung function improved 
and sputum P . aeruginosa density decreased during the treat-
ment period. Adverse events were minimal and consistent 
with standard symptoms of CF.29
Oermann and colleagues next reported a Phase II study 
evaluating the long-term safety and efficacy of AZLI.36 
This was an international 18-month open-label study which 
evaluated AZLI when used in alternating month cycles. 
Patients from 71 CF centers who participated in the previ-
ously described Phase II trials were eligible to participate. 
Study patients completed up to nine cycles (28 days on and 
28 days off) of AZLI with dosages of either 75 mg twice daily 
or three times daily, consistent with the dosing arm they had 
been assigned in their previous study. A total of 274 patients 
participated, with a mean age of 28.5 years.
Overall, long-term cyclical AZLI use was well tolerated, 
with the most common adverse events or side effects being 
consistent with expected CF symptoms. At the end of each 
treatment cycle, patients demonstrated improved FEV1, 
improved symptoms as measured by mean CFQ-R respiratory 
scores, and decreases in sputum P . aeruginosa density. Overall, 
patients maintained excellent adherence to long-term AZLI 
use (92% in the twice daily group and 88% in the three times 
daily group). Patients also demonstrated a sustained weight 
gain across the time frame of the study period.30
Most recently, Wainwright and colleagues described the 
results of a double-blind, multicenter, randomized, placebo-
controlled trial which evaluated the use of AZLI in CF 
patients with mild lung disease, defined by FEV1 . 75% of 
predicted.37 A total of 157 patients age 6 years and older were 
recruited from the US, Canadian, and Australian   centers. 
They were randomized to receive AZLI 75 mg three times 
daily vs placebo for 28 days with a 14-day follow-up period. 
The primary outcome measure was change from baseline in 
self-reported symptom scores as measured by the CFQ-R. Key 
secondary endpoints were change in lung function, change 
in sputum P . aeruginosa density, and use of additional antip-
seudomonal antibiotics.
While there was no significant difference in patient 
symptom scores, patients treated with AZLI had a significant 
decrease in sputum P . aeruginosa density and also a higher 
FEV1 at day 28. This change in lung function resulted primar-
ily from a decline in lung function among those receiving 
placebo. Furthermore, subanalysis of the primary endpoint 
among treatment groups revealed larger treatment effects in 
adult patients and those with baseline FEV1 , 90% predicted 
as compared to those with FEV1 $ 90% predicted. AZLI was 
well tolerated in this study.31
Ongoing and future AZLI studies
While the benefits of AZLI in patients with chronic 
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clinical trials, what remains to be determined is whether 
or not AZLI may benefit CF patients with other forms 
of endobronchial infection. For example, there is a clear 
need for additional therapies to treat patients infected 
with BCC, a particularly virulent Gram-negative infection 
characterized by multidrug resistance.38,39 The initial study 
of AZLI demonstrated in vitro activity against BCC,8 and 
a Phase III clinical trial is ongoing to further evaluate the 
potential benefit of AZLI in this unique CF patient popula-
tion (ClinicalTrials.gov Identifier: NCT010595). AZLI may 
also have potential benefits in other subsets of CF patients. 
For instance, a trial is planned evaluating AZLI’s effective-
ness as part of an early eradication treatment regimen for CF 
patients at the initial identification of P . aeruginosa infection. 
Finally, whether AZLI offers clinical benefit for the treatment 
of acute CF respiratory exacerbations needs to be determined 
by prospective studies.
Conclusions
As a result of extensive international evaluations 
  demonstrating consistent beneficial effects on lung func-
tion, patient-reported symptom scores, and other clinical 
measures such as the need for additional antipseudomonal 
antibiotics, AZLI was approved by the US Food and 
Drug Administration in 2010 for the treatment of chronic 
P . aeruginosa infection in patients with CF.40 The use of 
AZLI has been well accepted by many CF centers for 
use as an alternating on–off month cycle. A clear poten-
tial benefit for individual patients is the shorter duration 
of drug administration, thus resulting in less treatment 
burden and the potential for improved adherence. From 
the available clinical studies, it is reasonable to conclude 
that cycling monthly AZLI as mono-inhaled therapy, or as 
add-on therapy to other cyclical inhaled antibiotics such 
as tobramycin or colistin, may be both a clinically effica-
cious and well-tolerated therapy. At this time, since there 
are no available comparative efficacy studies, the decision 
to initiate a particular inhaled antibiotic therapy should 
be made based on available antibiotic sensitivity data for 
P . aeruginosa, patient-specific historical response to vari-
ous inhaled antibiotic therapies, and patient preference for 
delivery method.
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